- 专利标题： Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
-
申请号： EP11178187.8申请日： 2006-05-02
-
公开(公告)号： EP2418278A2公开(公告)日： 2012-02-15
- 发明人: Srinivasan, Mohan , Wang, Changyu , Selby, Mark, J. , Chen, Bing , Cardarelli, Josephine, M. , Korman, Alan, J.
- 申请人： ONO PHARMACEUTICAL CO., LTD. , Medarex, Inc.
- 申请人地址： 1-5, Doshomachi 2-chome Chuo-ku Osaka-shi, Osaka 541-8526 JP
- 专利权人： ONO PHARMACEUTICAL CO., LTD.,Medarex, Inc.
- 当前专利权人： ONO PHARMACEUTICAL CO., LTD.,Medarex, Inc.
- 当前专利权人地址： 1-5, Doshomachi 2-chome Chuo-ku Osaka-shi, Osaka 541-8526 JP
- 代理机构： Woods, Geoffrey Corlett
- 优先权： US679466P 20050509; US738434P 20051121; US748919P 20051208
- 主分类号： C12N15/09
- IPC分类号： C12N15/09 ; C07K16/28 ; C12N5/00 ; C12P21/08 ; C12Q1/02
摘要：
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
公开/授权文献
信息查询
IPC分类:
